Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Chemomab Therapeutics Ltd. (CMMB)

Chemomab Names Adi Mor CEO, Cuts Costs and Suspends Phase 2 SSc Trial Start

Mixed Impact 4 of 5 leadership Written later

Chemomab Therapeutics replaced CEO Dale Pfost and CFO Donald Marvin effective June 1, 2023, reappointing co-founder Adi Mor as CEO and Sigal Fattal as CFO, and named Nissim Darvish Chairman. The company also said it is implementing further cost-reduction measures to extend its cash runway to the end of 2024 and is suspending initiation of a Phase 2 systemic sclerosis trial to preserve capital.

Key points

  • Adi Mor appointed CEO effective June 1, 2023; her compensation will be set later and subject to shareholder approval
  • Sigal Fattal appointed CFO, replacing Donald Marvin, effective June 1, 2023
  • Cash runway expected to extend from mid-year 2024 to end of 2024, after the Phase 2 PSC topline data readout expected in the latter part of 2024
  • Former CEO Dale Pfost will receive 12 months of base salary in cash, accelerated stock option vesting and 12 months of COBRA premiums, subject to a separation agreement

The filing

CompanyChemomab Therapeutics Ltd. (CMMB)
Form8-K, current report
Filed with the SECJun 5, 2023, 7:00 AM ET
Accession number0001178913-23-002136

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 05, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.